~~<i id='1E928F3AC7'><strike id='1E928F3AC7'><tt id='1E928F3AC7'><pre id='1E928F3AC7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：explore 2025-10-02 13:41:10 - browse：334

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Physician assistants need a new name. Here's what it should be

focus

hotspot

leisure time

Wikipedia

knowledge

AdobeMedicareAdvantageisarguablythemostcontroversialhealthcareprogramrightnow—asentimentthatwasbolst

WSS

Medicare Advantage coverage denials need scrutiny, senators say

Problems with a popular proposal to regulate AI in health care

STAT Virtual Event: JPM Recap, Live!

A single Democrat is willing to weaken Medicare negotiation power

Padmanee Sharma of MD Anderson at center of lawsuit over credit

The CDC's new social media misinformation war

hotspot

hotspot

focus

Heart attack and stroke risk calculators need revising

The Biogen Aduhelm mess could happen again

In Memoriam: Notable people who died in 2023

Texas Medical Board asked to define abortion emergency exception

Hepatitis C has a cure — but many Americans still lack access to it

Gene therapy for Afghan refugees’ infant will be fully covered

State Dept. review finds Biden bears some blame for Afghanistan failures

Stories you might have missed in 2023: health, science, medicine

BioMarin wins approval for gene therapy to treat hemophilia A

JPM pitch from hospitals? Revenue streams outside of patient care

focus

The Biogen Aduhelm mess could happen again

A single Democrat is willing to weaken Medicare negotiation power

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Boston Scientific acquires urology company Axonics for $3.7 billion

Allen Institute goes after foundational questions, CEO Costa says

hotspot

leisure time

Wikipedia

knowledge